10x Genomics, Inc. Stock price

Equities

TXG

US88025U1097

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
37.53 USD +1.73% Intraday chart for 10x Genomics, Inc. -1.24% -32.93%
Sales 2024 * 679M Sales 2025 * 791M Capitalization 4.47B
Net income 2024 * -184M Net income 2025 * -107M EV / Sales 2024 * 6.12 x
Net cash position 2024 * 319M Net cash position 2025 * 363M EV / Sales 2025 * 5.2 x
P/E ratio 2024 *
-23.5 x
P/E ratio 2025 *
-41.6 x
Employees 1,259
Yield 2024 *
-
Yield 2025 *
-
Free-Float 84.78%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.73%
1 week-1.24%
Current month-19.53%
1 month-19.62%
3 months-34.79%
6 months-9.02%
Current year-32.93%
More quotes
1 week
35.38
Extreme 35.38
38.49
1 month
35.38
Extreme 35.38
46.86
Current year
35.38
Extreme 35.38
55.96
1 year
33.79
Extreme 33.79
63.57
3 years
23.81
Extreme 23.81
208.99
5 years
23.81
Extreme 23.81
208.99
10 years
23.81
Extreme 23.81
208.99
More quotes
Managers TitleAgeSince
Founder 47 12-07-01
Founder 49 12-07-01
Director of Finance/CFO 49 18-09-30
Members of the board TitleAgeSince
Chairman 66 13-07-31
Director/Board Member 65 20-03-25
Director/Board Member 57 17-08-22
More insiders
Date Price Change Volume
24-03-28 37.53 +1.73% 1,527,814
24-03-27 36.89 +1.77% 1,078,427
24-03-26 36.25 -0.17% 1,329,613
24-03-25 36.31 +0.06% 1,161,384
24-03-22 36.29 -4.50% 1,318,481

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
37.53 USD
Average target price
57.79 USD
Spread / Average Target
+53.97%
Consensus
  1. Stock
  2. Equities
  3. Stock 10x Genomics, Inc. - Nasdaq